The effect of weight loss following 18 months of lifestyle intervention on brain age assessed with resting-state functional connectivity

  1. Gidon Levakov  Is a corresponding author
  2. Alon Kaplan
  3. Anat Yaskolka Meir
  4. Ehud Rinott
  5. Gal Tsaban
  6. Hila Zelicha
  7. Matthias Blüher
  8. Uta Ceglarek
  9. Michael Stumvoll
  10. Ilan Shelef
  11. Galia Avidan
  12. Iris Shai
  1. Ben-Gurion University of the Negev, Israel
  2. University of Leipzig, Germany
  3. Soroka Medical Center, Israel

Abstract

Background: Obesity negatively impacts multiple bodily systems, including the central nervous system. Retrospective studies that estimated chronological age from neuroimaging have found accelerated brain aging in obesity, but it is unclear how this estimation would be affected by weight loss following a lifestyle intervention.

Methods: In a sub-study of 102 participants of the DIRECT-PLUS (dietary-intervention-randomized-controlled-trial polyphenol-unprocessed) trial, we tested the effect of weight loss following 18 months of lifestyle intervention on predicted brain age based on MRI-assessed resting-state functional connectivity (RSFC). We further examined how dynamics in multiple health factors, including anthropometric measurements, blood biomarkers, and fat deposition, can account for changes in brain age.

Results: To establish our method, we first demonstrated that our model could successfully predict chronological age from RSFC in three cohorts (n=291;358;102). We then found that among the DIRECT-PLUS participants, 1% of body weight loss resulted in an 8.9 months attenuation of brain age. Attenuation of brain age was significantly associated with improved liver biomarkers, decreased liver fat, and visceral and deep subcutaneous adipose tissues after 18m of intervention. Finally, we showed that lower consumption of processed food, sweets, and beverages were associated with attenuated brain age.

Conclusions: Successful weight loss following lifestyle intervention might have a beneficial effect on the trajectory of brain aging.

Funding: The German Research Foundation (DFG), German Research Foundation - project number 209933838 - SFB 1052; B11), Israel Ministry of Health grant 87472511 (to I Shai); Israel Ministry of Science and Technology grant 3-13604 (to I Shai); and the California Walnuts Commission (to I Shai).

Clinical Trial: This trial was registered at clinicaltrials.gov as NCT03020186.

Data availability

The code for the brain age prediction model and the calculation of brain age attenuation is openly available online at https://github.com/GidLev/functional_brain_aging. The unprocessed data used for the model training and validation is openly available online at http://fcon_1000.projects.nitrc.org/indi/enhanced/neurodata.html for the eNKI dataset and available upon online access request https://camcan-archive.mrc-cbu.cam.ac.uk/dataaccess/ for the CamCAN dataset. Data from the DIRECT-PLUS trial is not publicly available since it contains information that could compromise the privacy of research participants. However, de-identified data could be shared upon request, subject to approval from the Soroka Medical Center Medical Ethics Board. A processed version of the data that includes participants' demographics, predicted and observed age and weight values for T0 and T18 is available as supplementary information.

The following previously published data sets were used
    1. Nooner
    2. KB
    3. Colcombe
    4. SJ
    5. Tobe
    6. RH
    7. Mennes
    8. M
    9. Benedict
    10. MM
    11. Moreno
    12. AL
    13. Panek
    14. LJ
    15. Brown
    16. S
    17. Zavitz
    18. ST
    19. Li
    20. Q and Sikka
    21. S
    (2012) The NKI-Rockland sample
    Wide array of physiological and psychological assessments, genetic information, and advanced neuroimaging.

Article and author information

Author details

  1. Gidon Levakov

    Department of Cognitive and Brain Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    For correspondence
    gidonle@post.bgu.ac.il
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5520-3556
  2. Alon Kaplan

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  3. Anat Yaskolka Meir

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  4. Ehud Rinott

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  5. Gal Tsaban

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  6. Hila Zelicha

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  7. Matthias Blüher

    Department of Medicine, University of Leipzig, Leipzig, Germany
    Competing interests
    Matthias Blüher, has received consulting fees from Amgen, Astra Zeneca, Boehringer-Ingelheim, Bayer, Lilly, Novo Nordisk, Novartis, Sanofi and Pfizer; and fees for lectures/ presentations from Amgen, Astra Zeneca, Boehringer-Ingelheim, Bayer, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, Sanofi and Pfizer. The author is also on the advisory board for Boehringer-Ingelheim. The author has no other competing interests to declare..
  8. Uta Ceglarek

    Department of Medicine, University of Leipzig, Leipzig, Germany
    Competing interests
    No competing interests declared.
  9. Michael Stumvoll

    Department of Medicine, University of Leipzig, Leipzig, Germany
    Competing interests
    No competing interests declared.
  10. Ilan Shelef

    Department of Diagnostic Imaging, Soroka Medical Center, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
  11. Galia Avidan

    Department of Psychology, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2293-3859
  12. Iris Shai

    Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
    Competing interests
    No competing interests declared.

Funding

The German Research Foundation (209933838 SFB 1052; B11)

  • Iris Shai

Israel Ministry of Health (grant 87472511)

  • Iris Shai

Israel Ministry of Science and Technology (3-13604)

  • Iris Shai

California Walnuts Commission

  • Iris Shai

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: This work was based on a sub-study of the DIREC-PLUS trial (clinicaltrials.gov ID: NCT03020186). The Soroka Medical Center Medical Ethics Board and Institutional Review Board provided ethics approval. All participants provided written consent and received no financial compensation.

Copyright

© 2023, Levakov et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 7,535
    views
  • 753
    downloads
  • 10
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gidon Levakov
  2. Alon Kaplan
  3. Anat Yaskolka Meir
  4. Ehud Rinott
  5. Gal Tsaban
  6. Hila Zelicha
  7. Matthias Blüher
  8. Uta Ceglarek
  9. Michael Stumvoll
  10. Ilan Shelef
  11. Galia Avidan
  12. Iris Shai
(2023)
The effect of weight loss following 18 months of lifestyle intervention on brain age assessed with resting-state functional connectivity
eLife 12:e83604.
https://doi.org/10.7554/eLife.83604

Share this article

https://doi.org/10.7554/eLife.83604

Further reading

    1. Epidemiology and Global Health
    Marina Padilha, Victor Nahuel Keller ... Gilberto Kac
    Research Article Updated

    Background:

    The role of circulating metabolites on child development is understudied. We investigated associations between children’s serum metabolome and early childhood development (ECD).

    Methods:

    Untargeted metabolomics was performed on serum samples of 5004 children aged 6–59 months, a subset of participants from the Brazilian National Survey on Child Nutrition (ENANI-2019). ECD was assessed using the Survey of Well-being of Young Children’s milestones questionnaire. The graded response model was used to estimate developmental age. Developmental quotient (DQ) was calculated as the developmental age divided by chronological age. Partial least square regression selected metabolites with a variable importance projection ≥1. The interaction between significant metabolites and the child’s age was tested.

    Results:

    Twenty-eight top-ranked metabolites were included in linear regression models adjusted for the child’s nutritional status, diet quality, and infant age. Cresol sulfate (β=–0.07; adjusted-p <0.001), hippuric acid (β=–0.06; adjusted-p <0.001), phenylacetylglutamine (β=–0.06; adjusted-p <0.001), and trimethylamine-N-oxide (β=–0.05; adjusted-p=0.002) showed inverse associations with DQ. We observed opposite directions in the association of DQ for creatinine (for children aged –1 SD: β=–0.05; pP=0.01;+1 SD: β=0.05; p=0.02) and methylhistidine (–1 SD: β = - 0.04; p=0.04;+1 SD: β=0.04; p=0.03).

    Conclusions:

    Serum biomarkers, including dietary and microbial-derived metabolites involved in the gut-brain axis, may potentially be used to track children at risk for developmental delays.

    Funding:

    Supported by the Brazilian Ministry of Health and the Brazilian National Research Council.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Gillian AM Tarr, Linda Chui ... Tim A McAllister
    Research Article

    Several areas of the world suffer a notably high incidence of Shiga toxin-producing Escherichia coli. To assess the impact of persistent cross-species transmission systems on the epidemiology of E. coli O157:H7 in Alberta, Canada, we sequenced and assembled E. coli O157:H7 isolates originating from collocated cattle and human populations, 2007–2015. We constructed a timed phylogeny using BEAST2 using a structured coalescent model. We then extended the tree with human isolates through 2019 to assess the long-term disease impact of locally persistent lineages. During 2007–2015, we estimated that 88.5% of human lineages arose from cattle lineages. We identified 11 persistent lineages local to Alberta, which were associated with 38.0% (95% CI 29.3%, 47.3%) of human isolates. During the later period, six locally persistent lineages continued to be associated with human illness, including 74.7% (95% CI 68.3%, 80.3%) of reported cases in 2018 and 2019. Our study identified multiple locally evolving lineages transmitted between cattle and humans persistently associated with E. coli O157:H7 illnesses for up to 13 y. Locally persistent lineages may be a principal cause of the high incidence of E. coli O157:H7 in locations such as Alberta and provide opportunities for focused control efforts.